Physician profile
Beth Irwin
NPI 1174976989
$11,055.23
in general payments reported to CMS, 2019-2025
20 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,290 · 2022: $2,220 · 2023: $2,326 · 2024: $2,229 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,545.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,228.86 | 2021-2025 | Krystexxa, Evenity, Prolia |
| Ucb, INC. | $1,192.53 | 2021-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,175.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,063.30 | 2021-2025 | |
| Janssen Biotech, INC. | $877.05 | 2021-2025 | Simponi Aria, Tremfya |
| Astrazeneca Pharmaceuticals LP | $837.37 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $812.84 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $622.41 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $598.55 | 2021-2025 | Orencia |
| Pfizer INC. | $428.47 | 2021-2025 | |
| Lilly USA, LLC | $218.45 | 2021-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $207.41 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $203.27 | 2022-2023 | Lupkynis |
| Ani Pharmaceuticals, INC. | $179.25 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $157.61 | 2023-2025 | Tymlos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $99.06 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $92.41 | 2023-2025 | Tyenne, Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2025 | Ofev |
| Kiniksa Pharmaceuticals International, Plc | $21.94 | 2024 | Arcalyst |
| Sandoz INC. | $13.99 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.